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Interferon-stimulated genesPluripotent stem cells are being actively studied as a cell source for regenerating damaged liver. For long-term
survival of engrafting cells in the body, not only do the cells have to execute liver-speciﬁc function but also
withstand the physical strains and invading pathogens. The cellular innate immune system orchestrated by the
interferon (IFN) pathway provides the ﬁrst line of defense against pathogens. The objective of this study is to
assess the innate immune function as well as to systematically proﬁle the IFN-induced genes during hepatic
differentiation of pluripotent stem cells. To address this objective, we derived endodermal cells (day 5 post-
differentiation), hepatoblast (day 15) and hepatocyte-like cells (day 21) from human embryonic stem cells
(hESCs). Day 5, 15 and 21 cells were stimulated with IFN-α and subjected to IFN pathway analysis. Transcriptome
analysiswas carried out by RNA sequencing. The results showed that the IFN-α treatment activated STAT–JAK path-
way in differentiating cells. Transcriptome analysis indicated stage speciﬁc expression of classical and non-classical
IFN-stimulated genes (ISGs). Subsequent validation conﬁrmed the expression of novel ISGs including RASGRP3,
CLMP and TRANK1 by differentiated hepatic cells upon IFN treatment. Hepatitis C virus replication in
hESC-derived hepatic cells induced the expression of ISGs — LAMP3, ETV7, RASGRP3, and TRANK1. The
hESC-derived hepatic cells contain intact innate system and can recognize invading pathogens. Besides
assessing the tissue-speciﬁc functions for cell therapy applications, it may also be important to test the
innate immune function of engrafting cells to ensure adequate defense against infections and improve
graft survival.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Embryonic pluripotent stem cells are isolated from the inner cell
mass of developing primordial embryo. These pluripotent stem cells
have the ability to generate all cell types in the body. During tissueenerative Medicine Institute,
Angeles, CA 90048, USA.
aswami).
. This is an open access article underdamage, resident stem and progenitor cells can be activated to repair
and regenerate the damaged tissue. Transplantation of progenitor cells
derived from pluripotent stem cells is a promising therapeutic option
towards treating genetic, infectious and other degenerative disorders.
Transplanted cells at the site of injury encounter the inﬂammatory
niche comprised of cellular and soluble factors, including interferons
(IFNs). The engrafting cells respond to these stimuli by proliferation,
differentiation or cell death. These cell types could also be exposed to
infectious agents, such as pathogenic viruses and bacteria. In vitro
experiments have shown that embryonic pluripotent stem cells can
respond to type I (IFN-α and IFN-β) and II (IFN-γ) interferons thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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generating speciﬁc immunity (Whyatt et al., 1993; Drukker et al.,
2002; Hong and Carmichael, 2013). These observations are critical
for understanding the innate immune function of pluripotent stem
as well as progenitor cells and tissue rejection during cell therapy
application.
Interferons are a diverse family of cytokines which possess antiviral
and immunomodulatory properties (Isaacs and Lindenmann, 1957;
Stark et al., 1998; Theoﬁlopoulos et al., 2005). These specialized proteins
are produced by cells in response to viral infection. Cellular sensors such
as retinoic acid inducible gene I (RIG-I or DDX58) and toll like receptors
(TLR3, TLR7 and TLR9) can recognize pathogen associated molecular
patterns (PAMPs) that can trigger an innate immune response
(Thompson and Locarnini, 2007). Viral speciﬁc DNA, RNA and pro-
teins, and microbial products are sensed by TLR and RIG-I resulting
in the phosphorylation and activation of interferon regulatory factor 3
(IRF3) and IRF7 (Diebold et al., 2004; Gale and Foy, 2005; Perry et al.,
2005). Phosphorylated IRFs and NF-κB translocate to the nucleus and
transactivate the expression of IFN-α and IFN-β genes that are critical
in the elimination of invading pathogens. By autocrine and paracrine
means, the produced interferons serve as ligands for the Janus activated
kinase (JAK)–signal transducer and activator of transcription (STAT)
pathway (Horvath, 2004). Type I interferons bind to the IFN alpha/
beta receptors associated with two tyrosine kinases, JAK1 and TYK2
which phosphorylate STAT1 and STAT2 (Horvath, 2004). Both STAT
proteins bind with IRF9 generating the interferon stimulating gene 3
(ISGF3) complex (Kessler et al., 1990; Veals et al., 1993; Darnell et al.,
1994; Li et al., 1996). This complex is translocated to the nucleus
binding to the IFN-stimulated response element (ISRE) directing
the expression of IFN stimulated genes (ISGs) and converting the
host cell to an antiviral state (Muller et al., 1994; Haque and Williams,
1998; Liu et al., 2012). ISGs are involved in executing antiviral response
against pathogen like hepatitis C virus (Saito et al., 2008). ISGs function
in modulating various cellular processes, which includes altering the
cell cycle, apoptosis, angiogenesis, metabolism and transcriptional
regulation (Balachandran et al., 1998; Tan and Katze, 1999; de Veer
et al., 2001). There are over 300 canonical ISGs described and recently
genetic screens have been used for identiﬁcation of ISGs with antiviral
functions (Schoggins et al., 2011, 2014). Antiviral ISGs including GBP1,
MXA, CNP, cGAS, TAP1, RIG-I, MDA5 (IFIH1), IRF1 and LGP2 (DHX58)
are well characterized (Anderson et al., 1999; Kochs and Haller, 1999;
Yoneyama et al., 2005; Schoggins et al., 2011; Liu et al., 2012; Wilson
et al., 2012; Schoggins et al., 2014). Due to its antiviral properties,
IFN-α is a widely used therapeutic agent against HCV and hepatitis
B virus (HBV) that cause hepatitis, ﬁbrosis and cirrhosis (Schalm
et al., 2000; Manns et al., 2001).
Pluripotent stem cell-derived endodermal cells and hepatic lineage
cells are currently being tested for regenerating damaged liver in
preclinical animal models (Duan et al., 2007; Liu et al., 2011; Liu
et al., 2012). During embryonic development, hepatic lineage cells
originate from endoderm layer. Growth factors HGF, BMP, Wnt and
FGF signaling bymesenchymal cells are critical for liver development
(Schmidt et al., 1995; Uehara et al., 1995; Weinstein et al., 2001;
Michalopoulos, 2010). Using a combination of these growth factors,
pluripotent stem cells can be differentiated into hepatocytes via
endoderm (Cai et al., 2007; Rashid et al., 2010; Chen et al., 2012;
Cheng et al., 2012). This in vitro platform is useful for understanding
the differentiation stage-speciﬁc cellular perturbations for external
stimuli. Our objective is to investigate the innate immune response
exhibited by cells at different phases of hepatic differentiation
upon exposure to interferon (IFN-α) stimuli. We used an unbiased
discovery based approach to proﬁle ISGs during various hepatic
differentiation phases of pluripotent stem cells. We identiﬁed both
canonical and non-canonical ISGs, including novel ISGs. Functional
relevance of selected ISGs was veriﬁed during HCV replication in
differentiated hepatic cells.2. Materials and methods
2.1. Cells
Human embryonic stem cell (hESC) line, WA09 (H9), was sourced
from WiCell Research Institute, USA. The human induced pluripotent
stem cell (iPSC) line 83i-CTRL was obtained from Cedars-Sinai Medical
Center iPSC core facility and was described previously (Sareen et al.,
2012; Ren et al., 2015). The feeder-free hESCs were cultured using
serum-free chemically-deﬁnedmedia,mTeSR1 (STEMCELL Technologies,
Canada)with every daymedia change regimen. The HeLa cell line (ATCC,
USA) and human liver cancer cell lines, HepG2 and Huh-7.5.1, were
maintained using complete Dulbecco's modiﬁed Eagle's medium
(DMEM) (Fisher Scientiﬁc). Complete DMEM was supplemented with
10% fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin
(100 mg/ml), and 2 mM L-glutamine (Life Technologies). DMEMmedia
for HepG2 and Huh-7.5.1 cells contained additional supplements,
10 mM Hepes and 10 mM nonessential amino acids. All the cell lines
were maintained at 37 °C with 5% CO2.
2.2. Differentiation of pluripotent stem cells into hepatic lineage cells
For in vitro differentiation, single cell preparation of the pluripotent
stem cells was plated on a matrigel-coated 6-well plate, cultured at
37 °C in 5% CO2. The cells were subjected to a 3 week hepatic differenti-
ation protocol that consisted of three phases, including endoderm
induction (days 1–5), hepatic speciﬁcation (days 6–15) and hepatic
maturation (days 16–21). The protocol could yield endoderm cells
(day 5), hepatoblast (day 15) and hepatocyte-like cells (day 21). The
cytokines were procured from Peprotech Inc., (Rocky Hill, NJ) unless
otherwise mentioned. For differentiation we used a serum-free deﬁned
(SFD)media described by Cheng and colleagues (Cheng et al., 2012). SFD
base media comprised of IMDM (75%), Ham's F12 (25%) growth media
supplemented with N2 and B27 (without vitamin A) supplements (Life
Technologies). For endoderm differentiation, Wnt 3A (40 ng/ml, R and
D Systems) and Activin A (100 ng/ml) supplements were used in RPMI
media (Life Technologies) for the ﬁrst one day and the following four
days the cells were treated with Activin A, VEGF (10 ng/ml), BMP4
(0.5 ng/ml) and bFGF (10 ng/ml) in SFD media. From day 6 onwards,
the SFD media supplemented with BMP4 (50 ng/ml), VEGF (10 ng/ml),
EGF (10 ng/ml), TGF-α (20 ng/ml), HGF (100 ng/ml), dexamethasone
(1 × 10−7 M; Sigma-Aldrich, St. Louis, MO), DMSO (1%, Sigma-Aldrich),
ascorbic acid (50 μg/ml), and monothioglycerol (4.5 × 10−4 M) was
used. From day 12 onwards, BMP4 and TGF-α were removed from the
cocktail. For hepatocyte maturation phase, HGF, dexamethasone and
oncostatin M (20 ng/ml) were included in the SFD media from day 16
onwards. At indicated time points, endoderm and hepatic lineage speciﬁc
markers were assessed by immunocytochemistry (ICC), ﬂow cytometry
and reverse transcription-quantitative PCR (RT-qPCR).
2.3. IFN-α treatment
At day 5, day 15 and day 21 post-differentiation, the cells were
stimulated with human interferon-alpha A (R and D Systems) at a
concentration of 1000 IU or 5000 IU for 6 h. Untreated cells were
included as negative control. The 5000 IU IFN-α treated (D5, D15
and D21) and untreated (D5, D15 and D21) cell samples were collected
for RNA sequencing analysis and gene expression studies. Experiments
for RNA sequencing were done in duplicate with two independent
biological repeats (n = 2).
2.4. RNA sequencing sample preparation
Total RNA from cells was isolated using RNeasy Mini Kit (QIAGEN,
USA). RNase-Free DNase treatment was performed on column to remove
residual DNA. Twelve RNA samples were assessed for concentration and
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Spectrophotometer. RNA sequencing libraries were constructed using
Illumina TruSeq RNA Sample Preparation Kit v2 (Illumina, San Diego,
CA) per manufacturer's instructions. Brieﬂy, total RNA with RNA integ-
rity (RIN) scores of 9 or better using Agilent Bioanalyzer RNA6000 nano
kit were used for RNA library preparation. mRNA was then puriﬁed
from one microgram of total RNA from each sample using oligo-dT
attachedmagnetic beadswith two rounds of puriﬁcation. Subsequently,
themRNAwas fragmented and primed for cDNA synthesis according to
manufacturer's recommendations. RNA adapters and barcodes were
ligated to cDNA to allow for clonal ampliﬁcation and multiplexing on
a single lane on a single end Illumina ﬂow cell. Sequencing was done
on an Illumina HiSeq 2500 to an average read depth of 26 million
reads per sample and the minimum number of reads for a sample was
at least 23 million reads.
2.5. Quality assessment, ﬁltering and alignment of RNA sequencing
Raw Illumina reads in FASTQ format were analyzed for quality
control using RNASEQC (DeLuca et al., 2012). We assessed read depth,
average read length, average coverage across the gene, number of
genes identiﬁed, PCR duplication rate, ribosomal content, and exon/
intron representation to conﬁrm thequality of the library and sequencing.
Reads were aligned to the UCSC human reference genome (hg19) using
TOPHAT (Trapnell et al., 2009). Gene expression was calculated using
reference-guided transcript assembly using a gene transfer ﬁle (GTF)
from UCSC genes and normalized quantiﬁcation of reads as RPKM (# of
Reads Per Kilobase of ORF per Million reads aligned) calculated with
Cufﬂinks (Cufﬂinks, 2014) and compiled into a gene counts table for all
samples.
2.6. Gene expression ﬁltering
Reads Per Kilobase of transcript per Million mapped reads
(RPKM) were calculated for 51,057 genes. Raw FPKM (Fragments ߭Per
Kilobase߭of߭transcript per߭Million߭fragments߭mapped) values less than 1.1
were considered poorly measured and therefore increased to a min-
imum threshold of 1.1 to prevent overestimating gene expression
differences between groups of samples and to permit downstream analy-
seswhere data valuesmay be log-transformed. 30,616 geneswithout sig-
niﬁcant expression (FPKM= 1.1) were removed from further analysis,
leaving 20,441 genes. All gene expression values were log2 transformed.
2.7. Principle component analysis (PCA)
We ﬁrst assessed the data in an unbiased way for evidence of biolog-
ical or technical artifacts related to coordinated gene expression changes
by calculating the principle components and visualizing the greatest
three components of gene expression variance in a three-dimensional
plot (Supplementary Fig. S1). In this unsupervised analysis, we identiﬁed
the geneswith the highest variance independent of sample annotation by
ﬁrst calculating the standard deviations for each of the remaining 20,441
genes among all samples. Geneswere rank ordered by standard deviation
and the top 1000 genes were used to calculate the top three principal
components (PCA) and plotted using R (Vienna, Austria) version 3.0.2
package “rgl” (Adler and Murdoch, 2014).
2.8. Transcriptome analysis
2.8.1. Unique genes expressed
Wenext evaluated thedata for differences in gene expression during
differentiation time points (day 5, day 15 and day 21) or respective IFN-α
treatment conditions.Weﬁrst considered the number of genes expressed
in each stage and deﬁned a gene as well measured and expressed as
having an average of at least a FPKM of ﬁve in biological replicates from
1 time point/treatment. This stringent cut-off of 5 FPKM represents aslittle as one transcript per cell (Kellis et al., 2014). Thus, genes with
observations that averaged below 5 in a time point or treatment
were considered not expressed. In this way, we proposed a relative
number of unique genes that were expressed and shared among each
stage illustrated in a Venn diagram. The Venn diagram was generated
using program “Venny” (Oliveros, 2007).2.8.2. Differentially expressed genes (DEG)
We next set out to characterize the global gene expression effects
induced by differentiation or by IFN-α treatment. To do this, we selected
only genes that had an FPKM of 5 or greater in at least half the samples of
a comparison, andwere deﬁned aswellmeasured and expressed for anal-
ysis. In this way, for example, we identiﬁed for 12,617 genes as expressed
in at least two samples between day 5 and day 15 control samples and
11,009 genes between days 15 and 21.
A minimum of two fold change (the minimum fold change measur-
able byqPCR) and a false discovery rate of 10% (q b .1)were theminimum
criteria for all supervised analysis to deﬁne DEG. Q valueswere calculated
using two-tailed Student's t-test and applied the Benjamini andHochberg
adjustment for multiple hypothesis testing. For example, we identiﬁed
359 genes that were signiﬁcantly differentially expressed (fold change
at least 2, FDR at most 0.1) and 359 signiﬁcantly differentially expressed
genes fromdays 15 and21.We illustrated the gene expression differences
with a one-way hierarchical clustering analysis. The gene co-expression
correlations were calculated for all samples using “hclust”, and plotted
using “gplots” and “heatmaps.2”in R V2.14.2 (Warnes et al., 2014).
RNA Sequencing data is retrievable with GEO accession number
GSE67848.2.8.3. Pathway analysis
Signiﬁcantly expressed genes were assessed for pathway enrichment
using Ingenuity Pathway Analysis (IPA, 2014) (QIAGEN, Redwood City)
and signiﬁcantly enriched canonical pathways were deﬁned as having a
q-value b .1.2.9. Reverse transcription quantitative PCR analysis
Total RNAwas extracted from cells using RNeasyMini Kit (QIAGEN).
As a control, human primary hepatocyte RNA from fetal liver was
included. RNA samples were reverse-transcribed using SuperScript III
Reverse Transcriptase kit (Life Technologies) as recommended by the
manufactures using random primers. Gene expression was quantiﬁed
using Platinum SYBR Green qPCR SuperMix-UDG with ROX Kit (Life
Technologies) by the ViiA7 real-time PCR system (Applied Biosystems).
The reaction for each gene expression was completed in triplicates and
housekeeping human genes, PPIG (cyclophilin G) or GAPDH, were used
as an internal reference control. The qPCR primer sequences are given in
Supplementary Table S1. The following conditions were used for cDNA
ampliﬁcation: 50 °C for 2 min; 95 °C for 2 min followed by 40 cycles of
95 °C for 15 s and 60 °C for 1min. The Ct value of each gene is normalized
to that of the housekeeping gene to provide comparison among various
samples.2.10. Flow cytometry
At indicated time points, the differentiating cells were collected,
membrane permeabilized using the Cytoﬁx/Cytoperm kit (BD Biosci-
ences) and analyzed using antibodies against endoderm [SOX17 and
CXCR4 (R & D Systems)], and hepatic markers [AFP (Dako, USA) and
Albumin (Dako, USA)]. Cells were analyzed on a BD Fortessa (BD
Biosciences) ﬂow cytometer using FACSdiva software and FlowJo
software (TreeStar Inc.).
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Cells were ﬁxed with 4% paraformaldehyde (Polysciences, Inc.,
Warrington, PA). Following three PBS washes, the cells were blocked
with 10% fetal bovine serum, 3% BSA, and 0.1% Triton-X 100 in PBS.
Subsequently, the cells were incubated with human albumin goat
polyclonal primary antibody (Bethyl Laboratories, Inc) and alpha-1
antitrypsin (AAT) mouse monoclonal primary antibody (Santa Cruz
Biotechnology) at a dilution of 1:200 for overnight at 4 °C. The
secondary antibody, mouse anti-goat polyclonal antibody-FITC
(Santa Cruz Biotechnology) or goat anti-mouse polyclonal antibody
(Alexaﬂuor 594) (Life Technologies, USA)was added at 1:1000 dilutions
and incubated for 1 h at room temperature. Between antibody changes
the cells were washed ﬁve times with PBS. The nuclei were stained
with addition of Hoechst dye (Life Technologies, USA).
2.12. Western blotting
For Western blotting, the cell lysates were resolved by SDS-PAGE
using 4-15% gradient gel (Bio-Rad) and transferred to a PVDF
membrane using Trans-Blot turbo transfer system (Bio-Rad). The
membranes were blocked (5% skim milk, 0.2% Tween-20 in PBS) for
1 h at room temperature and probedwith rabbit monoclonal antibodies
STAT1, Phospho-STAT1 (Tyr701) and beta-actin (Cell Signaling Tech-
nology) and mouse monoclonal antibody NS3 [clone H23 (Abcam)].
Goat anti-rabbit or goat anti-mouse IgG conjugated with horseradish
peroxidase (Amersham Pharmacia Biotech) secondary antibody was
detected by chemiluminescence (SuperSignalWest PicoChemilumines-
cent Substrate kit, Thermo Scientiﬁc, USA).
2.13. Human apolipoprotein B-100 (ApoB-100) and triglyceride assays
24 hour spent culture media from differentiating cells (one million
cells per well) at indicated time points (day 0, day 4, day 10 and day
15 post-differentiation) were collected. The amount of ApoB-100
(ng/ml) produced by the cellswasmeasured by theHumanApolipopro-
tein B ELISA kit (MABTECH, Inc). Triglycerides (mg/ml) were measured
using colorimetric assay (L-Type TGM,Wako Diagnostics). Fold change
value to day 0 (undifferentiated cells) was obtained by calculating the
ratio with that of each time point.
2.14. Hepatitis C virus (HCV) genomic RNA generation and transfection
An intragenotype 2a chimeric virus, having genomic regions from
J6CF and JFH-1 strains was used in this study (Chu et al., 2013). Mutant
HCVwith catalytically inactive viral RNA polymerase NS5B (GDD amino
acids replaced with AAG residues) was reported previously (Chu et al.,
2013). T7-RNA polymerase-mediated in vitro transcription of HCV
plasmid DNA template was described previously (Chu et al., 2013; Ren
et al., 2014). The pFNX-HCV plasmids containing HCV cDNA were
linearized with XbaI restriction digestion and subjected to in vitro tran-
scription (T7 Ribomax Express Large Scale RNA Production System —
Promega Corporation, Madison, WI) and RNA puriﬁcation (Qiagen
RNeasy Mini Kit) as per manufacturer's recommendations. The hESC-
derived hepatic cells (day 14 post-differentiation) or Huh-7.5.1 cells
cultured in 12-well plates were used. HCV RNA (400 ng per well) was
transfected into the cells (1 × 106 per well) using TransIT mRNA
transfection reagent (Mirus Bio LLC., USA). 400 ng HCV RNA for
1 × 106 cells per well is non-cytotoxic as determined by viable cell
count at 24 h post-transfection of hESC-derived hepatic cells during
RNA dose optimization step. For mock control, the cells received only
transfection reagent without HCV RNA. After 4 h, the culture superna-
tant was replaced with fresh media. Samples were collected for RNA
and protein at indicated time points. For interferon treatment, 1000 IU
of IFN-αwas added once to cells 2 h before transfection.2.15. Statistical analysis
Error bars in the graph reﬂect the standard deviation. p-Values were
determined by the two-tailed Student's t-test and signiﬁcance was
reported if p value is p b 0.05 (*); p b 0.001 (**); and p b 0.0001 (***).
3. Results
3.1. Derivation of hepatic cells from pluripotent stem cells
To assess the cellular response to type-1 interferon during various
stages of hepatic differentiation, a three stage differentiation program
was used. This protocol recapitulates embryonic endoderm induction,
hepatic speciﬁcation and hepatic maturation phases (Fig. 1A) (Cai et
al., 2007; Rashid et al., 2010; Chen et al., 2012; Cheng et al., 2012). We
utilized feeder-free H9 human embryonic stem cells. First, we
evaluated the differentiation efﬁciency by investigating stage speciﬁc
markers. At day 5, over 85% cells co-expressed CXCR4 and SOX17
proteins demonstrating a robust endoderm induction (Fig. 1B). Then,
we evaluated hepatic markers by ﬂow cytometry to provide a quantita-
tive estimation of differentiation efﬁciency. At day 21, 85% of cells
expressed liver markers albumin and alpha-fetoprotein (AFP) (Fig. 1C).
Gene expression kinetics of albumin andAFP indicated that thesemarkers
are signiﬁcantly upregulated in differentiating cells at day 15 and day 21
compared to that of hESCs (Fig. 1D). At day15 today21, as thematuration
progressed, a trend of AFP reduction with an increase in albumin expres-
sion was observed. Positive controls of human primary hepatocytes of
fetal origin and liver cancer cell lineHepG2were included for livermarker
analysis. The results indicated that our three-phase differentiation proto-
col yielded fetal stage immature hepatocyte-like cells. Furthermore, we
tested the functionality of differentiating hepatic cells. The secretion of
very low-density lipoprotein (VLDL) particles is a hallmark characteristic
of hepatocytes. To test if the hepatic cells are competent for VLDL
secretion, we measured triglycerides (Fig. 1E) and ApoB-100 (Fig. 1F)
components of VLDL secreted into the culture media of one million cells
for a 24 hour period. Our results from differentiating hESCs and iPSCs
indicated that the hepatic lineage-speciﬁed cells at days 10 and 15 are
capable of releasing VLDL particles, thus reproducing physiological
function of liver. Additional liver marker, alpha-1 antitrypsin (AAT)
co-expression with albumin was demonstrated in differentiated-
hepatocyte-like cells by ICC (Fig. 1G).
We then assessed the differentiation-stage speciﬁc gene expression
by RNA sequencing analysis. 11009 genes were expressed at least one
time point (deﬁned as an average of FPKM N 5) (Fig. 2A). We observed
themost unique gene expression (2075 genes) in the earliest timepoint
(i.e. the hESC-derived endodermal cells) (Fig. 2A) and the largest num-
ber of differentially expressed genes (6165 genes) between the earliest
time points (day 5 and day 15) (Fig. 2B). On the contrary, we observed
fewer differences in later stages, for example the shared gene proﬁles
concurred with the differentiation states of the cells. Genes expressed
in day 15 cells were highly similar to day 21 cells, speciﬁcally only 359
genes out of the 11,009 expressed genes in day 15 and day 21 were
uniquely expressed in either time points (Fig. 2B). Furthermore, differ-
entially expressed genes at the liver-speciﬁed time points (day 15 and
day 21) demonstrate an enrichment of gene expression in liver speciﬁc
metabolic pathways, including urea cycle, and prothrombin activation
(Fig. 2C), while the cells at the earliest time point (day 5) expressed a
higher proportion of genes involved in embryonic development, pattern
formation, and in theBMP4pathway all ofwhich are consistentwith the
earliest phase of differentiation the endoderm. These data suggest the
cells likely determined their endoderm development fate by day 5 and
had differentiated into hepatic lineage by day 15 with little further
differentiation occurring after day 15. List of differentially regulated
genes are given in Supplementary Table S2. Taken together, we
established a robust hepatic differentiation platform for evaluating
type-1 IFN response pathway.
Fig. 1. Differentiation of hESC to hepatic lineage cells and gene expression analysis. (A) Schematic diagram depicting the experimental protocol used for the differentiation of hESCs into
hepatic lineage cells. Flow cytometry analysis of endoderm (B) and hepatic markers (C) by differentiating cells. In the histogram, the isotype l antibody stained cells are shown in red.
(D) Kinetics of liver speciﬁc-marker gene expression by RT-qPCR analysis. Expression of each gene is normalized to housekeeping gene PPIG and compared to that of day 0 hESCs.
Meanswith standard deviations are presented as bar graphs. HepG2 and primary human hepatocytes (PHH) from fetal liver are included as positive controls. (E and F) Functional analysis
of hepatic cells derived from hESC and iPSC lines. VLDL components, triglycerides and ApoB-100 production by differentiating cells at indicated time points are shown in the graphs.
(G) Immunocytochemistry of alpha 1 antitrypsin (AAT) and albumin expression by differentiating hepatocytes at day 25 (scale bar 10 μm).
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We chose cells from the endoderm phase (day 5) and the hepatic
phases (days 15 and 21) for assessing response to IFN-α. Type-1 IFN
exerts the biological effect by binding to IFN receptors and activating
the JAK–STAT pathway. The differentiating cells expressed the JAK–STAT
pathway genes, including type I interferon receptor 1 (IFNAR1), IFNAR2,
STAT1, STAT2 and IRF9 (Fig. 3A). Treatment of differentiating cells with
IFN-α for 1 h resulted in the phosphorylation of STAT1, a key component
of ISG3 transcription factor complex (Fig. 3B). Interestingly, the untreated
day 21 cells had higher basal level of phosphorylated form of STAT1
which could be due to use of oncostatin M (OSM), an IL-6 family of cyto-
kine that shares signaling pathwaywith STAT1. However, both IFN-α and
OSM have distinct receptors and downstream target genes resulting in
speciﬁc biological outcomes (Darnell et al., 1994; Heinrich et al., 1998;
Dey et al., 2013). Our results indicated that the JAK–STAT pathway can
be triggered by IFN-α in pluripotent stem cell-derived endoderm-
hepatic lineage cells.
To characterize the complete IFN response, we evaluated
transcriptomic differences between IFN-α treated (5000 IU for 6 h)
and matched untreated control samples at three different time
points (days 5, 15, and 21). First, we assessed whether the greatest
amount of gene expression variation between samples was associated
with biological conditions or another factor such as technical that
could affect downstream analysis. To do this, we calculated the top
three principal components and plotted them in 3D space (Supplemen-
tary Fig. S1). The samples clearly clustered based on differentiation time
points along with their respective IFN-treatment groups suggesting thelargest gene expression differences were associatedwith treatment and
time.
Next, we evaluated the ability of these cells especially the later-stage
differentiated cells to respond to IFN-α treatment (Fig. 4). We observed
that day 21 cells, a mature phase of differentiation, exhibited stronger
response to INF-α compared to that of day 5 and 15 cells. 438 genes
were signiﬁcantly upregulated (q-value 0.2 with 2 fold change)
between IFN-α treated and control day 21 samples (Fig. 4A). A list of
these genes can be found in Supplementary Table S3. Comparative anal-
ysis of previously known canonical ISGs indicated that 83 of the 438
genes were shared (Supplementary Table S3). Data for these IFN
induced 438 genes were ﬁlled in for day 15 IFN-α treated and control
samples regardless of fold change or signiﬁcance (Fig. 4A). 42 canonical
ISGswere signiﬁcantly changed in all three timepoints of differentiation
upon IFN treatment (Fig. 4B). The pathway analysis of differentially
regulated genes upon IFN treatment revealed the following innate
immunity pathways: interferon signaling, activation of IRF by cytosolic
pattern recognition receptors, role of pattern recognition receptors in
recognition of bacteria and viruses, antigen presentation pathway, role
of RIG1-like receptors in antiviral innate immunity, LPS/IL-1 mediated
inhibition of RXR function and virus entry via endocytic pathways. The
interferon signaling and virus entry via endocytic canonical pathways
with enriched genes are shown in Supplementary Fig. S2.
3.3. Validation of novel ISGs
For conﬁrmation, the IFN-α treatment (1000 IU and 5000 IU doses)
experiment was repeated on differentiating hES cells to hepatic cells.
Fig. 2. Global transcriptional analysis of differentiating hESCs by RNA-sequencing. (A) Venn diagram shows the shared and unique genes expressed at various stages of differentiation.
(B) Heat map of differentially expressed genes at days 5, 15 and 21 of differentiation (in duplicate; red-up regulated; green-down regulated). 2-Way supervised hierarchical clustering
was performed using 6313 unique genes speciﬁcally identiﬁed for each time point for the combined dataset. From day 5 to day 15 cells most of the 6165 genes were down-regulated.
Day 15 and day 21 cells had only 359 differentially expressed genes. (C) Canonical pathways activated in hepatic lineage cells are shown (day 5 = T1; day 15 = T2; day 21 = T3).
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canonical ISGs and novel hits from the transcriptome analysis, which
had a two-fold induction in at least two of the differentiation time
points studied. The canonical ISGs tested include, OAS1, LAMP3,
APOL2, TMEM140 and GBP1 (Fig. 5) as well as MX1, ISG15, HSH2D,
and ZNFX1 (Supplementary Fig. S3). We also veriﬁed the induction of
new candidate ISGs such as RASGRP3, TRANK1, and CLMP and less
characterized ISGs like ETV7, CNP and RBM43. Consistent with the
transcriptome proﬁle, the canonical ISGs, MX1, ISG15, OAS1, HSH2D,
and ZNFX1 had exhibited signiﬁcant IFN-mediated stimulation in all
three stages of cellular differentiation. The genes, LAMP3, TMEM140,
GBP1, RBM43 and ETV7 with no signiﬁcant change at day 5 due to
high FDR ranking (Supplementary Table S2), had strong induction on
all three time points as tested by RT-qPCR. RASGRP3 was veriﬁed as a
new ISG in differentiating cells (Fig. 5) as well as in human liver cancer
cell line Huh-7.5.1 and HeLa cells (Supplementary Fig. S3). Consistent
with transcriptome analysis, the genes TRANK1 and CLMP exhibited
insensitivity for IFN-α treatment at day 5, but were stimulated at day
15 and 21 post-differentiation. Induction level of APOL2 and CNP
remained relatively similar in cells of three differentiation phases. Our
result suggests that the validated genes exhibit differential induction
pattern during endodermal and hepatic differentiation states.3.3.1. Expression kinetics analysis
In addition to the 6 hr time point, we also tested the expression of
selected ISGs at 24 h post-IFN treatment. We studied the expression
kinetics of RASGRP3, TRANK1, CNP and ETV7. The OAS1 and LAMP3
genes were included as positive controls. In general, these ISGs showed
peak induction at 6 h post-IFN treatment (Fig. 6). At endoderm phase
(day 5), a marginal induction was observed for TRANK1 in 5000 IU
IFN treatment for 24 h. Since the genes were selected from the
transcriptome data of 6 h IFN treated samples, it was not surprising to
observe peak induction kinetic of 6 h. In conclusion, our data suggested
that the above tested ISGs have immediate early expression kinetics.3.4. Functional analysis of ISGs
In order to determine the biological relevance of the newly proﬁled
ISGs, we utilized a hepatitis C viral infection model. HCV is a major liver
pathogen affecting human. Hepatic cells derived from pluripotent stem
cells have been shown to be permissive for HCV replication (Schwartz
et al., 2012; Wu et al., 2012). RNA sequencing analysis showed that
the differentiating hepatic cells expressed various cell surface receptors
for HCV entry, including CD81, claudin 1 (CLDN1), occludin (OCLN),
Fig. 3. Analysis of JAK-STAT1 pathway in differentiating cells. (A) Basal expression values of factors involved in mediating the IFN-signaling pathway are given in the bar graph. The ab-
solute expression values were obtained from RNA-seq data of differentiating cells (without IFN-α treatment). (B) Analysis of STAT1 upon IFN-α treatment. Phosphorylated STAT1
(Tyr701)was detected following IFN-α addition to differentiating cells. Total STAT1 and actinwere included as loading controls. HeLa cells andHuh-7.5.1 cellswith orwithout IFN-α treat-
ment were included as positive controls. Note that the day 21 untreated cells have higher basal levels of pSTAT1.
360 J. Ignatius Irudayam et al. / Stem Cell Research 15 (2015) 354–364low-density-lipoprotein receptor (LDLR) and scavenger receptor class B
member 1 (SCARB1) (Supplementary Fig. S4) (Lindenbach and Rice,
2013). The day 14 differentiated cells (hepatic-speciﬁed can support
HCV growth) were transfected with HCV genomic RNAwith or withoutFig. 4. Transcriptome analysis of IFN-α treated differentiating cells. (A) Heat maps show differe
timepoints. Green depicts down-regulated gene levels and red induced levels. Expression levels
clustered according to their similarity in proﬁle. The dendrograms show unique clusters of ge
known canonical ISGs during differentiation upon IFN-α stimulation.IFN-α. The viral genome replication was tested using reverse tran-
scription quantitative-PCR assay. An increase in HCV genome level
was detected at 96 h post-transfection compared to that of 4 h
input indicating establishment of viral infection (Fig. 7A). The HCVntially regulated genes upon IFN-α treatment of differentiating cells at day 15 and day 21
of each gene indicatedby intensities are normalized in each row. Timepoints and genes are
nes according to common functionality. (B) Heat map depicts the expression levels of 42
Fig. 5. Validation of interferon induced genes proﬁled by RNA sequencing analysis. Day 5
(A), day 15 (B) and day 21 (C) cells treated with indicated doses of IFN-αwere subjected
to RT-qPCRanalysis. Relative geneexpression to untreated control cellswas calculated and
the mean values are shown in the graphs with standard deviations.
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the triggering of anti-viral response by IFN-α. Furthermore, HCV repli-
cation strongly induced the ISGs — LAMP3, OAS1 and ETV7 (Fig. 7B). A
marginal but signiﬁcant upregulation of RASGRP3, TMEM140 and
TRANK1 genes were also observed in HCV infected cells indicating an
indirect or direct role of these genes in innate immune response. Fur-
thermore, we carried out HCV replication experiment in humanhepatoma cell line (Huh-7.5.1) as an additional control. The results
indicated similar upregulation of IFN-stimulated genes with the
exception of OAS1 (Fig. 7C, D and E). We also observed a mild in-
duction of LAMP3 in HCV polymerase-null genomic RNA
transfected cells suggesting that the innate immune system can
be activated by viral PAMP in the non-functional genomic RNA to
a lesser extend (Fig. 7E). The ISG induction by HCV replication in
Huh-7.5.1 cells is likely through a RIG-I independentmanner, as the pa-
rental clone of Huh-7.5.1 line lacks RIG-I (Sumpter et al., 2005). Taken
together, the hepatic cells derived from H9 hESC retained an intact in-
nate immune system that is capable of sensing viral RNA andmounting
anti-viral response.4. Discussion
We utilized an unbiased RNA sequencing approach to proﬁle and
characterize IFN-stimulated genes during hepatic differentiation of
pluripotent stem cells. Our transcriptome analysis mainly focused on
protein-coding genes and approximately 20,441 genes were expressed.
Upon INF-α treatment, about 438 genes were signiﬁcantly induced at
day 21 cells including 83 canonical ISGs. Transcription of 42 ISGs were
signiﬁcantly changed by IFN-α in all three differentiation time points.
Our data suggested that the hESC-derived endoderm and hepatic cells
can positively respond to IFN, albeit with differences in gene expression
levels.
Murine embryonic stem cells have been shown to be responsive to
IFN-α and IFN-β (Whyatt et al., 1993). The undifferentiated hESC and
iPSC showed an attenuated type I interferon response that correspond
to high expression of SOCS1, a suppressor of cytokine signaling factor
(Hong andCarmichael, 2013).Here,wedemonstrate that the endodermal
phase cells are responsive to type I IFN. These in vitro observations
suggest that during in utero the developing embryo can respond to the
invading viral pathogens by up-regulating the innate defense system.
In the course throughout differentiation of hESCs, different cocktails
of cytokines and growth factors were used to achieve each phase of
hepatic lineage derivation (Fig. 1A). During IFN-α treatment, these
cytokine-infused cocktails could inﬂuence the gene expression proﬁle
by altering the activation of respective signaling pathways. For instance,
oncostatin M used during days 16 to 21 of differentiation can bind to
heterodimeric cell surface receptors- gp130 and either leukemia
inhibiting factor receptor (LIFR) or OSM receptor-beta (OSMR-beta)
resulting in activation of JAK–STAT, MAPK, and PI3K/AKT pathways
(Heinrich et al., 1998; Van Wagoner et al., 2000; Arita et al., 2008; Dey
et al., 2013). This variable was taken into account while calculating
gene transcription speciﬁcally altered upon IFN treatment by comparing
between IFN-α untreated (control) and treated cells of each endoderm,
hepatoblast and immature hepatocyte phases. The canonical ISGs,
including OAS1, ISG15 and MX1 were activated in all three phases;
whereas, the new ISGs TRANK1 and CLMP had a phase-speciﬁc expres-
sion proﬁle (Fig. 5). This observation could be biologically relevant as
various cell or tissue types subjected to differential epigenetic control to
accommodate speciﬁc functions.
Genes induced by IFN-α in various cell types have been proﬁled
previously (Der et al., 1998; Lanford et al., 2006; Liu et al., 2012).
Microarray analysis of primary human hepatocytes following IFN-α
treatment revealed the induction of LAMP3, OAS1, STAT1, GBP1, and
several other ISGs (Lanford et al., 2006). For validation of RNA sequenc-
ing data, we speciﬁcally focused on genes activated by IFN-α. LAMP3 or
CD208 regulates the transcription of anti-viral genes (Mohty et al.,
2003;Mine et al., 2013). LAMP3 is involved in the replication of inﬂuenza
virus and its expression is induced upon inﬂuenza viral infection (Zhou
et al., 2011). In the present study, induction of LAMP3uponHCV infection
suggests that the hESC-derived hepatic cells have the ability to mount
anti-viral response. LAMP3 can provide positive feedback signal to
augment the IFN-αmediated anti-viral response.
Fig. 6. Expression kinetics of selected ISGs. Induction of ISGs RASGRP3, ETV7, CNP and TRANK1 are shown for day 5 (A), day 15 (B) and day 21 (C) post-differentiation of hESCs. The well
characterized ISGs OAS1 and LAMP3 are included as positive controls. Normalized gene expression valueswere used for calculating the fold changewith that of unstimulated control and
presented as graphs. All the genes but TRANK1 were signiﬁcantly induced in 6 h and 24 h time points across differentiation phases.
Fig. 7. Functional validation of ISGs during hepatitis C virus replication. (A) HCV genome level was quantiﬁed by RT-qPCR. 4 hour time point indicates the equal amount of transfected RNA
in IFN-α untreated (HCV) and treated (HCV-IFN) cells. At 96 h post-transfection, the HCV replication was enhanced, but was inhibited in IFN-α treated cells. (B) HCV replication resulting
in theupregulation of ISGs. (C)Western blot analysis of HCVNS3protein production during viral replication. Protein lysates frommock transfected control cells, aswell asHCVpolymerase
null (Pol) andHCVwild type (WT) genomicRNA transfected cells at 96h post-transfectionwere used.β-Actinwas includedas a loading control. (D)HCV replication level inHuh-7.5.1 cells
is presented in the bar graph. The cellswere transfectedwith 1 μg of viral genomic RNA. At 96 h post-transfection, theHCV genome level was quantiﬁed and the fold changewas calculated
to that of control cells (mock transfected). (E) The ISGs induced in Huh-7.5.1 cells upon HCV replication at 96 h post-transfection are shown in the bar graph.
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363J. Ignatius Irudayam et al. / Stem Cell Research 15 (2015) 354–364ETV7 or TEL2, a transcription factor, may involve in hematopoietic
development and oncogenic transformation (Potter et al., 2000; Carella
et al., 2006). ETV7 expression had been shown to be induced in IFN-α
treated monocytes and HIV-1 infected cells (Rempel et al., 2008). We
observed that ETV7 was highly induced upon HCV replication. The role
of ETV7 during viral infection or IFN-mediated antiviral activity is
unknown, but may be attributed to regulating cell survival. RASGRP3
is a guanyl-nucleotide exchange factor which promotes the active
GTP-bound form of Ras. A recent report observed that the RASGRP3
acts as a negative regulator of inﬂammatory response by macrophages
through activating Rap1 (Tang et al., 2014). Induction of RASGRP3 dur-
ing HCV infection may be a cellular response to mitigate inﬂammatory
damage while mounting anti-viral defense. TRANK1 is a conserved
gene in mammals with no known function. The protein contains tetra-
tricopeptide and ankyrin repeats with a predicted hydrolase activity.
Our results indicate that TRANK1 is a novel ISG. TRANK1 mechanism
of action in the context of IFN-α signaling pathway and HCV infection
requires further investigation.
Host-pathogen interaction is a balancing act as viruses evolved to
have strategies to evade the host defense system. HCV NS3, core and
NS5A proteins are involved in immune evasion by modulating speciﬁc
and innate immune pathways (Basu et al., 2001; Horner and Gale,
2013). NS3 protease can effectively inactivate RIG-I by proteolysis,
thus negating the RIG-I mediated sensing of HCV RNA and activation of
downstream IRF-3 and NF-kB effectors (Korth and Katze, 2000; Gale
and Foy, 2005). Besides IFN-α, IL28 or IFN-λ, a type III IFN has been
shown to inhibit HCV replication by inducing ISGs (Thomas et al., 2012;
Zhou et al., 2014). Robust viral production is observed in sub-clones of
Huh-7 cell line that lack the innate immune sensor RIG-I and Huh-7
based cell lines have been commonly used for HCV studies (Lindenbach
et al., 2005; Sumpter et al., 2005; Wakita et al., 2005; Pietschmann
et al., 2006; Chu et al., 2013). Pluripotent stem cell-derived hepatic cells
is a useful model system for studying the interaction of innate immune
factors with hepatic pathogens, including HCV, hepatitis B virus (HBV)
and dengue virus. A previous study reported that the iPSC Hepatocytes-
like cells (iHLC) in response to HCV infection up-regulated antiviral
inﬂammatory genes (Schwartz et al., 2012). To further improve the
utility of human pluripotent stem cell lines for modeling patho-
physiological processes of innate immune system, individual or
combination of ISG knock-out cell lines could be established. Recent
advances in gene editing technologies through designer nucleases,
Zinc-ﬁnger nucleases (ZFN) and Transcription activator-like effector
nucleases (TALENs) as well as CRISPR (clustered regularly interspaced
short palindromic repeats)/Cas9 system, facilitate precise editing of
human genome by double-strand DNA breaks (Ding, Lee, et al., 2013a,
b; Ran et al., 2013).
Utilizing human pluripotent stem cell lines for modeling processes
of innate immune system can expand beyond studying viral infection;
furthermore, it can support human clinical trials by evaluating the cell
candidate population for transplant by measuring the presence of an
intact immune response to improve clinical outcome. For instance,
retinal pigment epithelium cells derived from iPSCs are currently
being evaluated in human clinical trials for an eye disorder and several
other stem cell-based preclinical studies are poised for human testing
(Trounson et al., 2011; Riken, 2013). Due to immuno-suppressive
treatment following allogeneic cell transplant and natural exposure to
pathogens in the environment, the recipients have the risk of complica-
tions from infectiousdiseases. To increase the chance of better therapeutic
outcome, the cell candidate for transplant can be evaluated for presence
of functional innate immune system.
5. Conclusion
Here, we describe the ﬁrst comprehensive analysis of the type I
IFN-induced gene proﬁle of endoderm and hepatic lineage cells
derived from pluripotent stem cells. The endodermal cells, hepatoblastand hepatocyte-like cells contained active type I IFN signaling pathway
which exhibited differential responses to IFN-α treatment. We identiﬁed
novel non-canonical ISGs such as RASGRP3, TRANK1 and CLMP. The
hESC-derived hepatic cells infected with HCV responded with upreg-
ulation of innate immunity genes LAMP3, OAS1, ETV7, RASGRP3, and
TRANK1 indicating that the novel ISGs may play a role in antiviral
response. The transcriptome proﬁle of various stages of hepatic
differentiation in combination with IFN-α treatment is a valuable
resource for understanding its basic biology as well as host-pathogen
interactions.
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